Brief: Assembly Biosciences Presents Data Of HBV Core Inhibitor Portfolio At Liver Meeting
12/11/2021 14:21
Nov 12 (Reuters) - Assembly Biosciences Inc ASMB.O :
* ASSEMBLY BIOSCIENCES PRESENTS NEW DATA AT AASLD THE LIVER
MEETING™ HIGHLIGHTING THE PROGRESS OF ITS HBV CORE INHIBITOR
PORTFOLIO
* ASSEMBLY BIOSCIENCES INC - ABI-H3733 SHOWS FAVORABLE
PHARMACOKINETICS AND SAFETY IN PHASE 1A STUDY; PHASE 1B STUDY
EXPECTED TO BEGIN IN 2022
Source text for Eikon: ID:nGNXc7rYFd
Further company coverage: ASMB.O
((Reuters.Briefs@thomsonreuters.com;))